Natural Alternatives International Inc (NAII) FinancialsNAIINatural Alternatives International Inc

Natural Alternatives International Inc (NAII) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Private Label Contract Manufacturing, accounting for 93.8% of total sales, equivalent to $31.76M. Another important revenue stream is Patent & trademark licensing. Understanding this composition is critical for investors evaluating how NAII navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Natural Alternatives International Inc maintains a gross margin of 1.08%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -11.31%, while the net margin is -12.15%. These profitability ratios, combined with a Return on Equity (ROE) of -20.57%, provide a clear picture of how effectively NAII converts its operational activities into shareholder value.

In the context of the broader market, NAII competes directly with industry leaders such as MTEX and ASBP. With a market capitalization of $14.37M, it holds a leading position in the sector. When comparing efficiency, NAII's gross margin of 1.08% stands against MTEX's 76.87% and ASBP's -47.68%. Such benchmarking helps identify whether Natural Alternatives International Inc is trading at a premium or discount relative to its financial performance.

The company has shown inconsistent revenue growth, with Q3 2026 net sales at $35.5 million, up from $28.8 million the previous year. However, net income has been negative, with a total net loss of $4.3 million reported for Q3 2026, and gross margins have fluctuated, with the latest at just 1.08%.